Strategy · KPIs
North Star Metric & KPIs
Closed-Loop Discovery Cycles Completed Per Quarter
One cycle = hypothesis generated by OmicsOS → experiment designed → executed via LabOS → data analyzed → validated insight confirmed. This is the fundamental unit of scientific value creation. Everything else derives from this.
The North Star captures both platform utilization and scientific rigor simultaneously. A company running 50 validated cycles per quarter is generating compounding scientific and commercial value. Secondary north star: ARR Growth Rate.
Platform Health
Monthly Active Users (MAU) on OmicsCloud
Data ingested (TB/month)
Pipeline runs per month
Time-to-first-insight (hours)
Discovery Engine
Target-to-validated hit (months)
DBTL cycles per program
Cost per validated datapoint
Experiment reproducibility rate (%)
Commercial
ARR ($)
Revenue per program ($)
Gross margin (%)
Net Revenue Retention (%)
Customer
NPS (target: >60)
Programs per active customer
Time-to-contract (sales cycle)
Customer churn (%/year)
Scientific IP
Biomarker assets in Atlas (#)
Patents filed/granted
Publications (peer-reviewed)
Co-development agreements
Lab Efficiency
Experiment throughput (runs/week)
Protocol automation rate (%)
CRO turnaround time (days)
Data quality score (%)
Year-by-Year Targets
| Metric | Year 1 | Year 2 | Year 3 | Year 5 |
|---|---|---|---|---|
| ARR | $500K | $3M | $10M | $50M+ |
| Active Customers | 5–8 | 20–30 | 60–80 | 200+ |
| Discovery Programs | 3–5 | 15–20 | 40–50 | 150+ |
| Closed-Loop Cycles/Qtr | 10 | 50 | 200 | 1,000+ |
| India Biomarker Atlas entries | 5,000 | 50,000 | 500K | 5M+ |
| Gross Margin | 40–50% | 55–65% | 65–70% | 75%+ |